Telehealth company Hims & Hers Health (NYSE: HIMS) will be reporting earnings this Monday afternoon. Here’s what you need to know.
Hims & Hers Health missed analysts’ revenue expectations by 1.1% last quarter, reporting revenues of $544.8 million, up 72.6% year on year. It was a mixed quarter for the company, with a beat of analysts’ EPS estimates but EBITDA guidance for next quarter missing analysts’ expectations significantly. It added 73,000 customers to reach a total of 2.44 million.
Is Hims & Hers Health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Hims & Hers Health’s revenue to grow 44.3% year on year to $579.6 million, slowing from the 77.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.23 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Hims & Hers Health has only missed Wall Street’s revenue estimates once over the last two years, exceeding top-line expectations by 3% on average.
Looking at Hims & Hers Health’s peers in the healthcare technology segment, only Omnicell has reported results so far. It beat analysts’ revenue estimates by 5%, delivering year-on-year sales growth of 10%. The stock traded up 13.6% on the results.
Read our full analysis of Omnicell’s earnings results here.Investors in the healthcare technology segment have had steady hands going into earnings, with share prices flat over the last month. Hims & Hers Health is down 11.8% during the same time and is heading into earnings with an average analyst price target of $47.77 (compared to the current share price of $46.35).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
